# PI3K/AKT/mTOR signaling in cancer

**Type:** Topics  
**Canonical URL:** https://scholariq.org/topics/pi3k-akt-mtor-signaling-in-cancer/

## Facts

| Field | Value |
| --- | --- |
| Description | This cluster of papers focuses on the mTOR signaling pathway, particularly its role in growth control, metabolism, and disease, with a specific emphasis on cancer. The PI3K/AKT pathway, Raptor, TSC2, and rapamycin are central to the research discussed in these papers. |
| Domain | Life Sciences |
| Field | Biochemistry, Genetics and Molecular Biology |
| OpenAlex ID | t10952 |
| Works | 223 |

## Topic papers all

Showing 15 of 223.

- [<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling](https://scholariq.org/papers/i-met-i-amplification-leads-to-gefitinib-resistance-in-lung-cancer-by-activating/)
- [Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma](https://scholariq.org/papers/temsirolimus-interferon-alfa-or-both-for-advanced-renal-cell-carcinoma/)
- [The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism](https://scholariq.org/papers/the-evolution-of-phosphatidylinositol-3-kinases-as-regulators-of-growth-and/)
- [Identification of the von Hippel-Lindau Disease Tumor Suppressor Gene](https://scholariq.org/papers/identification-of-the-von-hippel-lindau-disease-tumor-suppressor-gene/)
- [Targeting PI3K signalling in cancer: opportunities, challenges and limitations](https://scholariq.org/papers/targeting-pi3k-signalling-in-cancer-opportunities-challenges-and-limitations/)
- [Human insulin receptor and its relationship to the tyrosine kinase family of oncogenes](https://scholariq.org/papers/human-insulin-receptor-and-its-relationship-to-the-tyrosine-kinase-family-of/)
- [Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor](https://scholariq.org/papers/rapamycin-inhibits-primary-and-metastatic-tumor-growth-by-antiangiogenesis/)
- [Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy](https://scholariq.org/papers/loss-of-pten-promotes-resistance-to-t-cell-mediated-immunotherapy/)
- [Tuberous Sclerosis Complex Diagnostic Criteria Update: Recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference](https://scholariq.org/papers/tuberous-sclerosis-complex-diagnostic-criteria-update-recommendations-of-the/)
- [Akt Stimulates Aerobic Glycolysis in Cancer Cells](https://scholariq.org/papers/akt-stimulates-aerobic-glycolysis-in-cancer-cells/)
- [BRAF mutation predicts sensitivity to MEK inhibition](https://scholariq.org/papers/braf-mutation-predicts-sensitivity-to-mek-inhibition/)
- [Sirolimus for Angiomyolipoma in Tuberous Sclerosis Complex or Lymphangioleiomyomatosis](https://scholariq.org/papers/sirolimus-for-angiomyolipoma-in-tuberous-sclerosis-complex-or/)
- [Cardiotoxicity of the cancer therapeutic agent imatinib mesylate](https://scholariq.org/papers/cardiotoxicity-of-the-cancer-therapeutic-agent-imatinib-mesylate/)
- [Mechanisms of receptor tyrosine kinase activation in cancer](https://scholariq.org/papers/mechanisms-of-receptor-tyrosine-kinase-activation-in-cancer/)
- [The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers](https://scholariq.org/papers/the-genomic-landscape-of-endocrine-resistant-advanced-breast-cancers/)

## Topic primary papers

Showing 15 of 84.

- [The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism](https://scholariq.org/papers/the-evolution-of-phosphatidylinositol-3-kinases-as-regulators-of-growth-and/)
- [Targeting PI3K signalling in cancer: opportunities, challenges and limitations](https://scholariq.org/papers/targeting-pi3k-signalling-in-cancer-opportunities-challenges-and-limitations/)
- [Human insulin receptor and its relationship to the tyrosine kinase family of oncogenes](https://scholariq.org/papers/human-insulin-receptor-and-its-relationship-to-the-tyrosine-kinase-family-of/)
- [Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor](https://scholariq.org/papers/rapamycin-inhibits-primary-and-metastatic-tumor-growth-by-antiangiogenesis/)
- [Negative Regulation of Neural Stem/Progenitor Cell Proliferation by the <i>Pten</i> Tumor Suppressor Gene in Vivo](https://scholariq.org/papers/negative-regulation-of-neural-stem-progenitor-cell-proliferation-by-the-i-pten-i/)
- [A Pan-Cancer Proteogenomic Atlas of PI3K/AKT/mTOR Pathway Alterations](https://scholariq.org/papers/a-pan-cancer-proteogenomic-atlas-of-pi3k-akt-mtor-pathway-alterations/)
- [Antitumor Activity of Rapamycin in a Phase I Trial for Patients with Recurrent PTEN-Deficient Glioblastoma](https://scholariq.org/papers/antitumor-activity-of-rapamycin-in-a-phase-i-trial-for-patients-with-recurrent/)
- [Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma](https://scholariq.org/papers/complementary-genomic-approaches-highlight-the-pi3k-mtor-pathway-as-a-common/)
- [Dissecting eIF4E action in tumorigenesis](https://scholariq.org/papers/dissecting-eif4e-action-in-tumorigenesis/)
- [Targeting PI3K/AKT/mTOR pathway in non small cell lung cancer](https://scholariq.org/papers/targeting-pi3k-akt-mtor-pathway-in-non-small-cell-lung-cancer/)
- [Phase II Study of Temsirolimus (CCI-779), a Novel Inhibitor of mTOR, in Heavily Pretreated Patients With Locally Advanced or Metastatic Breast Cancer](https://scholariq.org/papers/phase-ii-study-of-temsirolimus-cci-779-a-novel-inhibitor-of-mtor-in-heavily/)
- [PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor–positive breast cancer](https://scholariq.org/papers/pi3k-inhibition-results-in-enhanced-estrogen-receptor-function-and-dependence-in/)
- [Phenotypic Spectrum Caused by Transgenic Overexpression of Activated Akt in the Heart](https://scholariq.org/papers/phenotypic-spectrum-caused-by-transgenic-overexpression-of-activated-akt-in-the/)
- [Important role of the LKB1–AMPK pathway in suppressing tumorigenesis in PTEN-deficient mice](https://scholariq.org/papers/important-role-of-the-lkb1-ampk-pathway-in-suppressing-tumorigenesis-in-pten/)
- [Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial](https://scholariq.org/papers/capivasertib-plus-paclitaxel-versus-placebo-plus-paclitaxel-as-first-line/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.